CYTOSORBENTS CORPORATION - COMMON STOCK

CytoSorbents to Present at the 8th Annual Dawson James Conference

05 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

27 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation

11 Sep 2023 11:32:17 By Nasdaq GlobeNewswire

CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico

01 Sep 2023 16:43:18 By Nasdaq GlobeNewswire

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents Reports Second Quarter 2023 Financial and Operational Results

01 Aug 2023 16:15:01 By Nasdaq GlobeNewswire

CytoSorbents to Report Second Quarter 2023 Operating and Financial Results

26 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer

19 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

11 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

07 Jul 2023 07:07:00 By Nasdaq GlobeNewswire

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

15 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference

05 Jun 2023 09:00:00 By Nasdaq GlobeNewswire

CytoSorbents Reports First Quarter 2023 Results

02 May 2023 16:15:00 By Nasdaq GlobeNewswire

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

26 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

CytoSorbents’ Pivotal STAR-T Trial Reaches Second Key Milestone With 80 Patients Enrolled

20 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

CytoSorbents Announces Board Chairman Al W. Kraus To Retire

19 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation

29 Mar 2023 08:30:00 By Nasdaq GlobeNewswire

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

22 Mar 2023 08:09:06 By Nasdaq GlobeNewswire

CytoSorbents Comments on Bank Exposure and Diversified Cash Position

14 Mar 2023 07:00:00 By Nasdaq GlobeNewswire